Joubert Syndrome

Joubert syndrome (JS) is a genetically heterogeneous neurodevelopmental ciliopathy defined by a characteristic cerebellar and brainstem malformation on axial brain MRI called the molar tooth sign. It is usually inherited in an autosomal recessive manner. Neurologic, visual, kidney, liver, respiratory, skeletal, feeding, and developmental involvement varies by person and genetic cause.[1,2]

Coding Note

The US ICD-10-CM code Q04.3 means “other reduction deformities of brain”; it is broader than Joubert syndrome and should not be treated as diagnostic confirmation.[3] Confirm coding with the current coding authority and the individual's documented manifestations.

Clinical Profile

Infants may have hypotonia, abnormal eye movements, and alternating apnea or rapid breathing. With age, motor delay and hypotonia often evolve into ataxia. Cognitive and adaptive outcomes span a broad range, and testing can underestimate ability when speech, motor, or visual access is not accommodated.[1,2]

Speech production can be affected out of proportion to language comprehension because oral-motor and speech apraxia are common. Dysphagia, drooling, and feeding difficulty may increase aspiration or nutritional risk. Other manifestations can include retinal dystrophy or coloboma, kidney disease, liver fibrosis, seizures, scoliosis, polydactyly, and sleep-disordered breathing.[1,2]

Diagnosis

Diagnosis requires the characteristic molar tooth sign on correctly interpreted brain MRI in the appropriate clinical context. Molecular testing can confirm a genetic cause, clarify inheritance, and help tailor surveillance, but a negative panel does not by itself exclude a clinically established diagnosis.[1,2]

Initial evaluation should assess breathing and sleep, feeding and aspiration risk, development, vision and eye movement, kidney and liver involvement, neurologic findings, growth, skeletal concerns, and family history. Genetics expertise is important because gene-specific risks and inheritance exceptions affect counseling and follow-up.[1,2]

Medical Management and Surveillance

Joubert syndrome has no single condition-specific treatment. Management is supportive and coordinated across the specialties relevant to the individual's manifestations. Seizures are treated using standard antiseizure approaches under an experienced clinician; no antiseizure medicine has been shown to be uniquely effective for JS.[1]

Ongoing surveillance is important because kidney, liver, retinal, respiratory, and other complications may emerge over time. The responsible clinician should use the molecular diagnosis, baseline findings, symptoms, and current recommendations to set the schedule rather than applying a generic checklist without context.[1,2]

Physical and occupational therapy may address mobility, ataxia, positioning, falls, fine-motor access, and daily activities. Low-vision, mobility, educational, nutrition, feeding, pulmonary, sleep, nephrology, hepatology, and mental-health services are added when indicated.[1,2]

Communication

Speech apraxia and dysarthria may make expressive communication appear more limited than comprehension. Do not estimate cognition, consent capacity, or language knowledge from speech output alone. Assessment should provide motor and visual accommodations and include observation with familiar partners.[1]

SLP support may address speech motor planning, intelligibility, language, and alternative communication. AAC can be introduced when speech does not reliably meet the person's needs and can coexist with speech development. Preserve access to a broad range of communication functions, including refusal, pain, fatigue, choices, social connection, and medical information.[1,4]

JS does not prescribe a specific device or access method. Oculomotor apraxia, nystagmus, reduced vision, ataxia, hypotonia, head movement, and fatigue can affect touch, eye-gaze, or switch performance. Compare options through direct trials, include positioning and sensory access, and retain a low-tech backup and an agreed yes/no signal. Partner-assisted scanning may be a backup when independently controlled access is temporarily unreliable, not an automatic endpoint.[4]

The general evaluation, device-trial, funding, and acquisition process is described in AAC Device Acquisition.

Feeding and Swallowing

Assess oral intake safety and nutrition throughout care. Warning signs include coughing or choking, wet or congested voice after eating, drooling with feeding difficulty, prolonged meals, recurrent respiratory illness, dehydration, or poor growth. Concern warrants evaluation by the appropriate feeding and swallowing team; instrumental assessment may be needed to assess aspiration.[1,2]

Diet modification, supplemental nutrition, or gastrostomy decisions require individualized discussion with the person or family and the treating SLP, nutrition, gastroenterology, and medical teams. They should not be prescribed from diagnosis alone.[1]

Education and Participation

Educational planning should separate motor, visual, speech, and access barriers from learning ability. Provide sufficient response time, accessible materials, a reliable communication mode, and opportunities to demonstrate knowledge without requiring speech or rapid eye-hand responses.

Goals may address communication, literacy, mobility, daily living, social participation, and self-advocacy. Review access as vision, motor control, fatigue, environments, and academic demands change.[1]

Urgent Boundaries

Apnea with color change, marked breathing difficulty, or failure to recover requires emergency care. Promptly assess suspected aspiration, acute dehydration, reduced urine output, jaundice, a first or prolonged seizure, abrupt neurologic change, or rapid loss of function. Anesthesia and surgery teams should be told about the diagnosis and any breathing, airway, kidney, liver, or cardiac history before a procedure.[2]

Support

• Joubert Syndrome & Related Disorders Foundation
• National Organization for Rare Disorders: Joubert syndrome

References

1. Bachmann-Gagescu R, Dempsey JC, Bulgheroni S, et al. Joubert Syndrome. GeneReviews. Updated February 12, 2026.
2. Bachmann-Gagescu R, Dempsey JC, Phelps IG, et al. Healthcare recommendations for Joubert syndrome. American Journal of Medical Genetics Part A. 2020;182:229–249.
3. Centers for Medicare & Medicaid Services. FY 2026 ICD-10-CM definitions: Q04.3 Other reduction deformities of brain.
4. American Speech-Language-Hearing Association. Augmentative and Alternative Communication Practice Portal. Accessed July 21, 2026.